

Joanna Mangana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9078281/publications.pdf>

Version: 2024-02-01

66
papers

1,314
citations

430874

18
h-index

434195

31
g-index

66
all docs

66
docs citations

66
times ranked

2230
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutaneous SCC with orbital invasion: case series. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 59-62.	2.4	5
2	EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600E-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF/MEK inhibition.. Journal of Clinical Oncology, 2022, 40, 9540-9540.	1.6	5
3	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
4	The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. European Journal of Cancer, 2021, 144, 215-223.	2.8	9
5	Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany. , 2021, 9, e001701.		23
6	Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [18F]FDG PET/CT. European Radiology, 2021, 31, 8011-8020.	4.5	12
7	A multicentre study of naevus-associated melanoma vs. <i>de novo</i> melanoma, tumour thickness and body site differences*. British Journal of Dermatology, 2021, 185, 101-109.	1.5	13
8	Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.. Journal of Clinical Oncology, 2021, 39, 9533-9533.	1.6	1
9	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. European Journal of Cancer, 2021, 149, 37-48.	2.8	12
10	Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.. Journal of Clinical Oncology, 2021, 39, 9578-9578.	1.6	1
11	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2021, 22, 836-847.	10.7	104
12	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. Cancers, 2021, 13, 2931.	3.7	19
13	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Annals of Oncology, 2021, 32, 917-925.	1.2	76
14	Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers, 2021, 13, 3830.	3.7	12
15	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	2.8	12
16	Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. Lancet Oncology, The, 2021, 22, e343-e344.	10.7	2
17	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. European Journal of Cancer, 2021, 156, 149-163.	2.8	11
18	Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center. Oncotarget, 2021, 12, 125-130.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Binimetinib in heavily pretreated patients with NRAS mutant melanoma with brain metastases. <i>British Journal of Dermatology</i> , 2020, 182, 488-490.	1.5	6
20	Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. <i>Melanoma Research</i> , 2020, 30, 552-561.	1.2	5
21	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy†. <i>Annals of Oncology</i> , 2020, 31, 1075-1082.	1.2	62
22	The role of cyclin D1 and Ki67 in the development and prognostication of thin melanoma. <i>Histopathology</i> , 2020, 77, 460-470.	2.9	13
23	Targeting complex, adaptive responses in melanoma therapy. <i>Cancer Treatment Reviews</i> , 2020, 86, 101997.	7.7	8
24	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10005-10005.	1.6	26
25	Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10011-10011.	1.6	8
26	The nature and management of acquired resistance to PD1-based therapy in melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10014-10014.	1.6	4
27	Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis. <i>European Journal of Dermatology</i> , 2020, 30, 699-709.	0.6	1
28	Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 730.	7.1	2
29	Eight autopsy cases of melanoma brain metastases showing angiotropism and pericytic mimicry. Implications for extravascular migratory metastasis. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 570-578.	1.3	14
30	Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. , 2019, 7, 50.		44
31	Serum S100B Levels in Melanoma. <i>Methods in Molecular Biology</i> , 2019, 1929, 691-700.	0.9	8
32	How I treat metastatic melanoma. <i>ESMO Open</i> , 2019, 4, e000509.	4.5	2
33	Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2019, 42, 29-32.	2.4	49
34	Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. <i>Melanoma Research</i> , 2019, 29, 65-69.	1.2	27
35	The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in rapidly accelerated fibrosarcoma-mutated advanced melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 686-692.	2.4	17
36	Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma. <i>Melanoma Research</i> , 2019, 29, 648-654.	1.2	8

#	ARTICLE	IF	CITATIONS
37	A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy.. Journal of Clinical Oncology, 2019, 37, 9502-9502.	1.6	6
38	Melanoma patients with additional primary cancers: a single-center retrospective analysis. Oncotarget, 2019, 10, 3373-3384.	1.8	4
39	Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget's disease. Oncotarget, 2019, 10, 6647-6650.	1.8	9
40	Sustainable responses in metastatic melanoma patients with/without brain metastases after immunotherapy induced CR.. Journal of Clinical Oncology, 2019, 37, e21042-e21042.	1.6	0
41	Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma. European Journal of Cancer, 2018, 93, 147-149.	2.8	10
42	Update on adjuvant melanoma therapy. Current Opinion in Oncology, 2018, 30, 118-124.	2.4	12
43	Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research. Transplantation Direct, 2018, 4, e376.	1.6	98
44	Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. Melanoma Research, 2018, 28, 442-450.	1.2	14
45	A new B-Raf inhibitor combo for advanced melanoma. Oncotarget, 2018, 9, 34457-34458.	1.8	2
46	A Report of Two Cases of Solid Facial Edema in Acne. Dermatology and Therapy, 2017, 7, 167-174.	3.0	4
47	Successful retreatment with combined <scp>BRAF</scp>/<scp>MEK</scp> inhibition in metastatic <scp>BRAF</scp>V600E-mutated melanoma. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1638-1640.	2.4	12
48	Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome). Case Reports in Dermatology, 2017, 9, 74-79.	0.8	5
49	Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. Melanoma Research, 2017, 27, 358-368.	1.2	20
50	Developments in targeted therapy in melanoma. European Journal of Surgical Oncology, 2017, 43, 581-593.	1.0	45
51	Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma. Annals of Oncology, 2017, 28, 1673-1675.	1.2	11
52	Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.. Journal of Clinical Oncology, 2017, 35, 9512-9512.	1.6	6
53	NRAS-mutated melanoma patients have similar response rates to therapy with checkpoint inhibitors as other cohorts.. Journal of Clinical Oncology, 2017, 35, e21035-e21035.	1.6	1
54	An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. British Journal of Dermatology, 2016, 175, 966-978.	1.5	8

#	ARTICLE	IF	CITATIONS
55	Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. <i>British Journal of Dermatology</i> , 2016, 174, 823-830.	1.5	26
56	Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. <i>Scientific Reports</i> , 2016, 6, 29914.	3.3	99
57	A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. <i>ESMO Open</i> , 2016, 1, e000003.	4.5	32
58	Efficacy and safety of oral alitretinoin in severe oral lichen planus – results of a prospective pilot study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 293-298.	2.4	23
59	Diffuse Cutaneous Melanosis Associated with Malignant Melanoma. <i>Annals of Dermatology</i> , 2015, 27, 780.	0.9	1
60	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. <i>PLoS ONE</i> , 2015, 10, e0139438.	2.5	27
61	Real life experience with check point and kinase inhibitors in Swiss advanced melanoma patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20064-e20064.	1.6	0
62	Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9096-9096.	1.6	57
63	Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. <i>Journal of Clinical Oncology</i> , 2013, 31, 9025-9025.	1.6	4
64	Sorafenib in melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 557-568.	4.1	48
65	Prevalence of Merkel Cell Polyomavirus among Swiss Merkel Cell Carcinoma Patients. <i>Dermatology</i> , 2010, 221, 184-188.	2.1	35
66	Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome. <i>European Journal of Dermatology</i> , 2008, 18, 566-70.	0.6	25